119 related articles for article (PubMed ID: 3187951)
1. Antithrombin III Avranches, a new variant with defective serine-protease inhibition--comparison with antithrombin III Charleville.
Aiach M; Roncato M; Chadeuf G; Dezellus P; Capron L; Fiessinger JN
Thromb Haemost; 1988 Aug; 60(1):94-6. PubMed ID: 3187951
[TBL] [Abstract][Full Text] [Related]
2. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
[TBL] [Abstract][Full Text] [Related]
3. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
Tripodi A; Krachmalnicoff A; Mannucci PM
Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
[TBL] [Abstract][Full Text] [Related]
4. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
[TBL] [Abstract][Full Text] [Related]
5. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
Jørgensen M; Petersen LC; Thorsen S
J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
[TBL] [Abstract][Full Text] [Related]
6. Homozygous variant of antithrombin III: AT III Fontainebleau.
Boyer C; Wolf M; Vedrenne J; Meyer D; Larrieu MJ
Thromb Haemost; 1986 Aug; 56(1):18-22. PubMed ID: 3775688
[TBL] [Abstract][Full Text] [Related]
7. Antithrombin III Alger: a new homozygous AT III variant.
Fischer AM; Cornu P; Sternberg C; Mériane F; Dautzenberg MD; Chafa O; Beguin S; Desnos M
Thromb Haemost; 1986 Apr; 55(2):218-21. PubMed ID: 3715788
[TBL] [Abstract][Full Text] [Related]
8. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
[TBL] [Abstract][Full Text] [Related]
9. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
Wolf M; Boyer-Neumann C; Meyer D; Tripodi A; Mannucci PM; Larrieu MJ
Thromb Haemost; 1987 Oct; 58(3):888-92. PubMed ID: 3433251
[TBL] [Abstract][Full Text] [Related]
10. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
Tran TH; Bondeli C; Marbet GA; Duckert F
Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
[TBL] [Abstract][Full Text] [Related]
11. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville.
Aiach M; Nora M; Fiessinger JN; Roncato M; François D; Gelas MA
Thromb Res; 1985 Sep; 39(5):559-70. PubMed ID: 4082101
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA
Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579
[TBL] [Abstract][Full Text] [Related]
13. Homozygous or compound heterozygous qualitative antithrombin III deficiency.
Cucuianu M; Blaga S; Pop S; Olinic D; Olinic N; Colhon D; Cristea A
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):335-7. PubMed ID: 7971256
[TBL] [Abstract][Full Text] [Related]
14. Familial variant of antithrombin III (AT III Bligny, 47Arg to His) associated with protein C deficiency.
Wolf M; Boyer-Neumann C; Molho-Sabatier P; Neumann C; Meyer D; Larrieu MJ
Thromb Haemost; 1990 Apr; 63(2):215-9. PubMed ID: 2363123
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity.
Howarth DJ; Samson D; Stirling Y; Seghatchian MJ
Thromb Haemost; 1985 Jun; 53(3):314-9. PubMed ID: 4049307
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation.
Molho-Sabatier P; Aiach M; Gaillard I; Fiessinger JN; Fischer AM; Chadeuf G; Clauser E
J Clin Invest; 1989 Oct; 84(4):1236-42. PubMed ID: 2794060
[TBL] [Abstract][Full Text] [Related]
17. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis.
Okajima K; Abe H; Maeda S; Motomura M; Tsujihata M; Nagataki S; Okabe H; Takatsuki K
Blood; 1993 Mar; 81(5):1300-5. PubMed ID: 8443391
[TBL] [Abstract][Full Text] [Related]
18. Antithrombin III molecular variants with defective binding to heparin or to serine proteases: evidence of two different abnormal patterns identified by crossed immunoelectrofocusing.
Leone G; De Stefano V; Ferrelli R; Teofili L; Tengborn L; Vahtera E; Bizzi B
Thromb Haemost; 1988 Aug; 60(1):8-12. PubMed ID: 3187949
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biochemical characterization of antithrombin III Franconville, a variant with Pro 41 Leu mutation.
de Roux N; Chadeuf G; Molho-Sabatier P; Plouin PF; Aiach M
Br J Haematol; 1990 Jun; 75(2):222-7. PubMed ID: 2372510
[TBL] [Abstract][Full Text] [Related]
20. [Abnormal antithrombin III: abnormalities of heparin or protease binding domain].
Sakuragawa N; Niiya K; Takahashi K; Hayashi T; Oguma Y; Saitoh S
Rinsho Byori; 1993 May; 41(5):492-505. PubMed ID: 8350512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
